Robert Dillman

Robert Dillman

Company: Aivita Biomedical

Job title: Chief Medical Officer


Using the Antigenic Signature of Self-renewing GBM Cells to Target Low & High Mutational Tumor Burden 9:45 am

Autologous dendritic cells loaded with autologous tumor antigens from self-renewing tumor initiating cells as personal therapeutic cancer vaccines Lessons learned from a single-arm phase 2 trial in primary GBM Randomized, blinded phase 3 trial in primary GBMRead more

day: Conference Day 2

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.